Autophagy LC3 p38 MAPK PKC activation by combining TPA with sodium butyrate (T/B) represents the most effective and widely used strategy to induce the Epstein-Barr virus (EBV) lytic cycle. The results obtained in this study show that novel PKCθ is involved in such process and that it acts through the activation of p38 MAPK and autophagy induction. Autophagy, a mechanism of cellular defense in stressful conditions, is manipulated by EBV to enhance viral replication. Besides promoting the EBV lytic cycle, the activation of p38 and autophagy resulted in a prosurvival effect, as indicated by p38 or ATG5 knocking down experiments. However, this pro-survival role was counteracted by a pro-death activity of PKCθ, due to the dephosphorylation of AKT. In conclusion, this study reports, for the first time, that T/B activates a PKCθ-p38 MAPK axis in EBV infected B cells, that promotes the viral lytic cycle and cell survival and dephosphorylates AKT, balancing cell life and cell death.
Introduction
Protein kinases C (PKCs) are serine/threonine kinases that regulate many cellular functions, in cell type-specific manner, and whose activity is in turn regulated by serine/threonine and tyrosine phosphorylation [1] [2] [3] .
PKCs include several isoforms classified into three major subgroups: classical, novel and atypical PKCs. The first two groups are activated by phorbol esters such as 12-O-tetradecanoylphorbol-13-acetate (TPA), which mimics the effect of diacylglycerol (DAG), the degradation product of phoshatidylinositol, the conventional activator of the classical and novel PKCs. Differently from the classical PKCs, that require the presence of calcium, novel PKCs are calcium independent [4, 5] . Finally, the atypical PKCs do not require neither DAG nor calcium, being phosphatidylserine [6] sufficient for their activation [7] . Besides the differences in their activation, PKC isoforms differ in their structure, tissue distribution and subcellular localization [8, 9] . The latter is influenced by the activation status and by the interaction with molecules [10] such as RACKs/RICKs (receptors for activated/inactive kinase) [11, 12] , PICK1 (protein interacting with C-kinase-1) [13, 14] and STICKs (substrates interacting with C kinase) [15] .
Activated PKCs interact with signaling pathways that regulate cell survival and differentiation such as MEK-ERK, Raf1 and c-Jun [16] as well as STAT1, STAT3 and NF-κB [17] [18] [19] [20] [21] [22] . In particular, PKC theta (PKCθ), a member of the novel PKCs, has been shown to regulate the activation of MKK4, a kinase that acts upstream of p38 and JNK MAPK in T lymphocytes [23, 24] , and is involved in PMA-mediated NF-κB activation also in B cells [25] . The treatment with TPA, by strongly activating PKCs, efficiently induces the Epstein-Barr virus (EBV) lytic cycle in cells in which the virus establishes a latent infection [26] [27] [28] [29] .
EBV is an oncogenic virus, associated with several human cancers, such as Burkitt's lymphoma (BL), in which the majority of cells harbor a latent infection in-vivo. The TPA-mediated EBV lytic cycle activation can be potentiated by its combination with sodium butyrate (T/B) [30, 31] , that has been shown to differently influence PKC activation [32] . PKC activation is also involved in Ca ionophore [33] and nocodazole mediated EBV lytic cycle activation [34] . In particular, a role for the novel PKCs has been demonstrated in the histone deacetylase mediated EBV reactivation from latency, as indicated by the use of rottlerin, a novel PKC specific inhibitor [35] . However, it has been reported that the EBV lytic cycle can be triggered, in some instances, independently of PKC activation [36] .
We have previously shown that PKC activity is required for EBV infection of human B cells [37] and, in this study, we investigated the PKC isoform/s activated by T/B in the EBV-infected B cells, their role and the mechanisms through which they induce the viral lytic cycle.
We found that the novel PKCθ was strongly activated by T/B and that it played an essential role in the EBV lytic cycle induction. Our's and other's laboratories have recently demonstrated that autophagy promotes EBV replication [38, 39] and since PKCθ is required for autophagy induction during Endoplasmic Reticulum (ER) stress [40, 41] , we next investigated whether PKC theta could promote the EBV lytic cycle through autophagy induction. Moreover, since p38 MAPK, that plays an essential role in EBV reactivation from latency [42] , is involved in autophagy induction [43, 44] and since p38 phosphorylation may be mediated by PKCθ in other cell types [23, 24] , we then asked if T/B could activate a PKCθ-p38 axis in EBV infected B cells, promoting the viral lytic cycle through autophagy induction. The autophagic process was monitored by the biochemical analysis of autophagic markers LC3II (lipidated form of LC3 that is formed during the autophagic process) and p62 (a protein specifically degraded through autophagy) [45] .
It has been demonstrated that the activation of novel PKCs, such as PKC delta (PKC δ), can induce both cell death and cell survival [46] . Similarly, here we found that PKCθ activation resulted in a pro-survival effect due to p38 and autophagy induction but, on the other hand, it was involved in the dephosphorylation of AKT mediated by T/B. PKCs have been previously reported to mediate the inhibition of AKT pathway in the course of TPA treatment, in keratinocytes [47] . AKT represents an important pro-survival pathway in BL cells [48] as well as in other lymphoma's cells [49] . Understanding the role and the mechanism/s through which the different PKCs act in regulating viral replication and cell survival is of pivotal importance to develop specific inhibitors, to be used in the clinical practice against EBV associated malignancies.
Materials and methods

Cell cultures and reagents
B95-8 [50] , P3HR1 [51] , Akata [52] and Raji are EBV positive B cell lines [53] , 293-EBV derived from 293 cell lines and are stably transfected with B95.8 genomes (kindly provided by H.J. Delecluse) [54] . Cells were grown in RPMI 1640 (Sigma-Aldrich R0883) supplemented with 10% heat inactivated fetal bovine serum (FBS) (EuroClone ECLS0 180L), glutamine (2 mM) streptomycin (100 g/ml) and penicillin (100 U/ml Aurogene AU-L0022-100), in 5% CO 2 at 37°C. The EBV lytic cycle was induced with TPA (12-O-tetradecanoylphorbol13-acetate) (Sigma-Aldrich P1585) and sodium butyrate (Sigma-Aldrich B5887) were used at a final concentration of 40 ng/ml and 6 mM in B95-8 cells, 20 ng/ml and 3 mM in P3HR1 cells, and by anti-IgG (50 μg/ml, Millipore 56961) crosslinking in Akata cells. The cells were pre-treated with p38 inhibitor (SB203580, Sigma-Aldrich S8307), JNK inhibitor (SP600125, Santa Cruz sc-200635), ERK inhibitor (PD98059, Sigma-Aldrich P215) and PI3K/ATK inhibitor (LY294002, Sigma-Aldrich P0037) at 20 μM for 30 min and then, treated with TPA and sodium butyrate. Novel PKC inhibitor rottlerin (Santa Cruz sc-3550) was added at final concentrations of 5, 10, 20 μM for 1 h before transfection.
Virus production from 293-EBV cell line and Raji superinfection
293-EBV cells were grown in six-well cluster plates, pretreated with different concentrations of rottlerin for 1 h and then, were transfected with the expression plasmid containing the gene for BZLF1 (0.5 μg each/well) (pBZLF1) (p509), (kindly provided by Prof. Delecluse), by using lipid micelles (Metafectene; Biontex) to induce lytic replication [54, 55] . Four days after transfection, culture supernatants were harvested, filtered through a 0.45 μm and used to superinfect Raji cells (500 μl supernatant/10 5 Raji cells). Three days after superinfection Raji cells were analyzed by FACS and scored for GFP expression.
Western blot analysis
Cells were lysed in modified RIPA buffer (150 mM NaCl, 1% NP40, 50 mM Tris-HCl pH 8, 0.5% deoxycholic acid, 0.1% SDS, 1% Triton X-100 protease and phosphatase inhibitors) and 30 μg of each lysate were loaded on 4-12% NuPage Bis Tris gels (Life Technologies NP0323BOX) electrophoresed and transferred to Nitrocellulose membrane (Whatman, GE Healthcare 10401196). Membranes were blocked for 30 min at RT in PBS containing BSA 3% and 0.2% Tween 20, then incubated with primary antibody overnight at 4°C, washed three times with PBS 0.2% Tween 20 and probed with appropriate secondary HRP-conjugated secondary antibody (Santa Cruz Biotechnologies). After 3 washes as described before, the membranes were subjected to ECL reaction with a blotting substrate (Advansta 12045-D20).
Antibodies
For Western blot analysis, the following primary antibodies were used: rabbit polyclonal anti-LC3 (1:1000) (Novus Biologicals NB100-2220SS), rabbit polyclonal anti-phospho PKC-theta (1:200) (Cell Signaling 9377P), rabbit polyclonal anti-p38 (1:500) (Cell Signaling 9212), rabbit polyclonal anti-phospho p38 (1:500) (Cell Signaling 4631P), rabbit polyclonal anti-AKT (1:500) (Cell Signaling 9272S), rabbit polyclonal anti-phospho AKT (Cell Signaling 4060S) (1:500), rabbit polyclonal anti-phospho JNK (1:500) (Cell Signaling 4668P), rabbit polyclonal anti-JNK (1:500) (Cell Signaling 9258P), rabbit polyclonal anti-ERK (1:500) (Santa Cruz sc-93 mixed with Santa Cruz sc-154), rabbit polyclonal anti-phospho ERK (1:300) (Cell Signaling sc-7383), rabbit polyclonal anti-cleaved PARP p85 (1:1000) (Promega G7341), rabbit polyclonal anti-ATG5 (1:1000) (Novus Biological NB110-53818), mouse monoclonal anti BFRF1 was developed in our lab (1:50) [56] , mouse monoclonal anti-ZEBRA (1:100) (Santa Cruz sc-53904), mouse monoclonal anti-p62 (1:1000) (BD Transduction Laboratories 610833), mouse monoclonal anti-RTA (1:500) (Argene), mouse monoclonal anti-EA-D (1:1000) (Millipore 8186), mouse monoclonal anti-β-actin (1: 10000) (SIGMA A2228), mouse monoclonal anti-GAPDH (1:1000) (Santa Cruz sc-137179), mouse monoclonal antitubulin (Sigma-Aldrich T5168) (1:1000).
Goat anti-rabbit IgG-horseradish peroxidase HRP (1:10 4 ) (Santa Cruz sc-2004) and goat anti-mouse IgG-horseradish peroxidase HRP (1:10 4 ) (Santa Cruz sc-2005) were used as secondary antibodies. All of the primary and secondary antibodies used in this study were diluted in a PBS-0.2% Tween 20 solution containing 3% BSA.
Immunofluorescence
Cells were seeded on multispot slides and fixed in 2% paraformaldehyde for 30 min at RT, washed 3 times in PBS and permeabilized with 0.5% Triton X-100 for 5 min at RT; then blocked with a solution containing 3% BSA 1% glycin for 30 min at RT. Samples were incubated with primary antibodies for 1 h at RT then, after washing in PBS, the appropriated conjugated secondary antibodies were added and finally the samples were stained with DAPI (Sigma-Aldrich D9564). Microscope slides were mounted using PBS-glycerol 1:1 and visualized by a Apotome axio observer Z1 inverted microscope (Zeiss Oberkochen, Germany), equipped with an Axiocam MRM Rev.3 camera at 40 × magnification.
For immunofluorescence analysis the following primary antibodies were diluted in PBS as the following: rabbit polyclonal antiphospho-PKCμ (Cell Signaling) rabbit polyclonal anti-phospho PKCαβ (1:50), and mouse monoclonal anti-ZEBRA (1:100) (Santa Cruz sc-53904).
Secondary antibodies were diluted in PBS as the following: TRITC-conjugated goat anti-rabbit (1:300) (Jackson 111-025-003), Alexa Fluor-488 conjugated goat anti-rabbit (1:200) (Invitrogen A11008), Cy3 conjugated sheep anti-mouse (1:1000) (Jackson 515-165-062).
Genes knockdown by siRNA
The knockdown of PKCθ, p38 and ATG5 was performed by specific small interfering RNA according to the manufacturer's instructions (Santa Cruz sc-36247, sc-29433, sc-41445 respectively).
Briefly the day before transfection 4 × 10 5 cells were seeded in six-well culture plates in a RPMI medium without antibiotics. Subsequently 100 pmol of specific small interfering RNA (siRNA duplex) or non-targeting (scramble) siRNA and 10 μl of transfection reagent (Lipofectamin 2000 Life Technologies 11668027) were diluted in Opti-MEM medium (Life Technologies 31985062) and added to the cells according to the manufacturer's instruction. To evaluate transfection efficiency a fluorescein conjugate control siRNA (Santa Cruz sc-36869) was also included in each experiment. The cells were treated with TPA and sodium butyrate 24 h after transfection and collected the day after treatment. Finally cells were counted by trypan-blue exclusion assay using a hemocytometer and pelleted for protein extraction. Each experiment was performed in triplicate.
Statistics
All experiments unless differently indicated were performed at least three times. All the experimental results were expressed as arithmetic mean ± standard deviation (s.d.). Student's t-test was used for statistical significance of the differences among treated groups. Statistical analysis was performed using analysis of variance at 5% (p = 0.05) or 1% (p = 0.01).
Results
Novel PKC activity is required for T/B mediated EBV lytic cycle activation
We investigated the role of the novel PKCs in P3HR1 BL cells induced to lytic cycle by T/B. To this aim, the cells were treated with T/B for 24 h, in the presence or in the absence of rottelerin, a novel PKC specific inhibitor ( [57, 58] ). As shown in Fig. 1A , the expression level of EA-D, an early lytic EBV antigen, progressively decreased in the presence of an increasing amount of rottlerin, indicating that novel PKCs play an essential role in the induction of EBV lytic cycle by T/B, in BL cells. Next, rottlerin was used to inhibit EBV replication also in 293-EBV cells in which recombinant EBV-B95-8 genomes were stably transfected [54] . To induce a virus production, 293-EBV cells were transiently transfected with a plasmid which encodes the ZEBRA protein. After 96 h, the virus supernatants were used to infect the Raji cells. Functional viral titers were determined via GFP expression of infected Raji cells. The number of green Raji units per milliliter was calculated as a measurement of the infectious particle concentration in virus stock [55] . As shown in Fig. 1B , the expression of RTA, an immediate early EBV antigen, whose expression is soon induced by ZEBRA transfection, was strongly reduced in the presence of rottlerin [59] . Finally, to assess whether the inhibition of novel PKCs would also impair viral production, the supernatant of 293-EBV cells, induced to lytic cycle by ZEBRA transfection, in the presence or in the absence of increasing amount of rottlerin, was used to superinfect Raji cells. We found that, accordingly to the inhibition of EBV lytic antigen expression, rottlerin strongly inhibited the 293-EBV supernatant infectivity on Raji cells, assessed by counting the GFP-positive cells by serial dilutions (Fig. 1C) . These results confirm the importance of the novel PKCs in the activation of EBV lytic cycle.
PKCθ is involved in EBV reactivation from latency by T/B
P3HR1 cells, treated with T/B to induce EBV reactivation from latency, were analyzed by immunofluorescence assay (IFA), to investigate the activation of novel (θ and δ), classical (α/β), and atypical (μ) PKCs, using polyclonal antibodies directed against the phosphorylated forms of the molecules. The EBV lytic cycle induction by T/B was assessed by detecting the expression of the EBV early antigen BFRF1 ( Fig. 2A ). We found that PKCθ and to a much lesser extend δ, α/β or μ PKC isoforms were activated upon 24 h of T/B treatment ( Fig. 2A) . Similar results were obtained in the marmoset B lymphoblastoid B95-8 cells, undergoing EBV lytic cycle by the same treatment (data not shown). We next performed a double IFA for BFRF1 and PKCθ to evaluate, at a single cell level, whether PKCθ was specifically activated in cells undergoing EBV replication, either spontaneously or upon T/B treatment. The results shown in Fig. 2B indicate that in the great majority of P3HR1 and B95-8 cells expressing BFRF1, PKCθ was strongly activated and that it was mostly localized in the cell nuclei. Finally, as shown in the same figure, we siRNA, before treatment with T/B and the expression of the immediate early lytic EBV antigen ZEBRA was evaluated by Western blot analysis. We found that PKCθ knocking down strongly reduced ZEBRA expression, in comparison to scramble treated cells ( Fig. 2C ). Of note, the activation of PKCθ by T/B resulted in the appearance of a cleaved form of this molecule, as described for other activated PKCs [60] .
p38 MAPK plays a positive role in EBV replication and affects the autophagic pathway in EBV-infected B cells treated with T/B
MAPK kinases are reported to be activated in EBV-infected Raji BL cells, in which an abortive lytic cycle was induced by T/B [42] . In this study we investigated whether these kinases were activated also in the B cells able to support a complete EBV lytic program, upon T/B treatment. The results shown in Fig. 3A indicate that p38 MAPK and to a lesser extent JNK and ERK phosphorylations were induced by T/B, after 24 h of treatment. The role of these kinases in the EBV lytic cycle was then evaluated by treating B95-8 cells with T/B in the presence or in the absence of p38, JNK or ERK inhibitors, SB203580, SP600125 or PD98059, respectively. According to the results previously obtained in Raji cells [42] , ZEBRA expression was more strongly reduced by SB203580 in comparison with SP600125 or PD98059, indicating that p38 MAPK plays a major role in the activation of the EBV lytic program in B95-8 cells (Fig. 3B ). Looking for a mechanism/s underlying the EBV lytic Fig. 6 . PKCθ balances pro-survival and pro-death pathways in B95-8 cells. B95-8 cells knocked down for p38 MAPK or scramble treated were exposed to T/B for 24 h and (A) cell survival was evaluated by Trypan blue assay (*p = 0.02) and (B) PARP cleavage together with the ZEBRA EBV lytic protein and p38 were investigated by Western blot analysis. B95-8 cells knocked down for ATG5 or for PKCθ or scramble treated were exposed to T/B for 24 h and (C) cell survival was evaluated by Trypan blue assay (**p = 0.02) and (D) PARP cleavage together with RTA EBV lytic protein were assessed by Western blot analysis. (E) The level of AKT phosphorylation was evaluated in B95-8 cells knocked down for PKCθ or scramble treated and exposed to T/B for 24 by Western blot analysis. (F) The level of AKT phosphorylation was evaluated in B95-8 cells knocked down for p38 MAPK or scramble treated and exposed to T/B for 24 by Western blot analysis. Total AKT and/or GAPDH were also included as control. A representative experiment is shown and the means plus standard deviations of the densitometric analysis of the specific proteins on GAPDH of three independent experiments is also reported. cycle induction by p38, we investigated if it could mediate the induction of autophagy, whose positive role in EBV replication has been recently demonstrated by our's and other's laboratories [38, 39] . We found that the level of the lipidated form of LC3 (LC3II), arising during the autophagic process induced by T/B, was strongly reduced by SB203580, p38 inhibitor, concomitantly with the reduction of ZEBRA expression ( Fig. 3B ), suggesting that p38 MAPK is involved in autophagy induction by T/B. ZEBRA expression and LC3II level were less influenced by PD98059 and SP600125 (Fig. 3B) , indicating that ERK and JNK play a minor role in both lytic cycle and autophagy activation. Since LC3II is formed and degraded through autophagy, it does not allow by itself to evaluate the completeness of the process. So, we then analyzed the expression level of p62, a protein that represents a read-out of a bona fide autophagic process. As shown in Fig. 3B, p62 level increased in the presence of SB203580 in combination with T/B, further supporting that idea that p38 is involved in the autophagy induction. The importance of p38 MAPK in the EBV lytic cycle activation was then confirmed in the P3HR1 BL cells induced to lytic cycle by T/B treatment ( Fig. 4A and B ).
A PKCθ-p38 MAPK axis promotes EBV-lytic cycle through autophagy induction
Since novel PKCs can act upstream of MAPKs [61, 62] , we then investigated whether the phosphorylation of p38 MAPK could depend on PKCθ activation and both kinases could promote the EBV lytic cycle, through autophagy induction. To this aim, the level of p38 phosphorylation as well as the autophagic markers LC3 I/II and p62 were evaluated in B95-8 knocked down for PKCθ, by Western blot analysis. PKCθ silencing was revealed by the reduction of its cleaved form, known to be produced during T/B treatment [60] , (Fig. 5A and B ). We found that p38 phosphorylation and LC3II expression level were reduced while p62 accumulated in PKCθ knocked down cells, in comparison with the scramble treated control, upon T/B treatment ( Fig. 5A and B) , as a result of an autophagic block. Concomitantly to the block of autophagy, the expression of the EBV early lytic protein EA-D was reduced by PKCθ knock down ( Fig. 5A and B ). All together these data indicate that PKCθ mediate the phosphorylation of p38 MAPK which, in turn, promoted the EBV lytic cycle by inducing autophagy. A reduction of the percentage of ZEBRA expressing cells was then observed by IFA in B95-8 knocked down PKCθ or p38 MAPK, in comparison to scramble or control cells, (Fig. 5C ), confirming that both kinases play a positive role in the EBV reactivation from latency.
PKCθ at the cross-roads between cell survival and cell death
PKCθ phosphorylation by T/B induces p38 MAPK activation that in turn promotes autophagy in B95-8 cells. p38 has been reported to promote cell survival during the activation of the EBV lytic cycle [42] and autophagy is also usually a pro-survival mechanism, especially during stressful conditions, such as during treatment with cytotoxic therapies [63, 64] . Based on this knowledge, we next investigated the role of p38 in cell survival, by knocking down this molecule with specific siRNA. We found that cell survival was reduced and PARP cleavage increased in p38 knocked down cells treated with T/B in comparison with scramble control ( Fig. 6A and B) . A similar effect on cell survival and PARP cleavage was then obtained by knocking down ATG5, an essential autophagic gene ( Fig. 6C and D) , confirming the pro-survival role of both p38 and autophagy activation during T/B treatment. Surprisingly, the percentage of cell survival and PARP cleavage did not increase in cells knocked down for PKCθ, in comparison with the scramble control, upon T/B treatment ( Fig. 6C and D) , suggesting that PKCθ, besides being involved in pro-survival effects, is acting on other/s pathways that induce cell death. Of note, the silencing of p38, ATG5 and PKCθ reduced the EBV immediate early lytic protein expression ( Fig. 6B and D) , further supporting the idea that these molecules belong to a common pathway leading to the EBV lytic cycle activation.
Since PKC activation can reduce AKT phosphorylation [47] and AKT represents an important pro-survival pathway in lymphoma cells [49] , including BL cells [48, 49] , we next investigated if PKCθ could be involved in the AKT dephosphorylation mediated by the T/B treatment. We found that AKT phosphorylation was less affected in PKCθ knockeddown B95-8 cells, in comparison with the scramble control treated with T/B (Fig. 6E ), suggesting that PKCθ is able to balance cell survival and cell death in B cells, in which it promotes the EBV replicative cycle. Differently from PKCθ, p38 silencing slightly influenced AKT dephosphorylation induced by T/B (Fig. 6F ), in agreement with the pro-survival role of p38 in the course of the T/B treatment ( Fig. 6A and B ). Next, we investigated the role of AKT in the EBV lytic cycle by inhibiting its activity with Ly294002 (Ly) in B95-8 cells induced to lytic cycle by T/B. According to previous studies on EBV replication [65, 66] , we found that Ly reduced the expression of BFRF1 EBV lytic antigen, confirming that PI3K/ AKT axis was involved in the induction of the EBV lytic cycle (Fig. 7A ). Finally, we investigated whether the dephosphorylation of AKT induced by PKCθ would contribute to its mediated autophagy induction in B95-8 cells treated with T/B. At this aim, we inhibited AKT with Ly 294002 in cells knocked down for PKCθ, before the T/B treatment. The results reported in Fig. 7B , showing that p62 level was slightly affected by Ly treatment, suggest that PKCθ-mediated AKT dephosphorylation plays a minor role on autophagy induction.
Discussion
In this study, we show that PKCθ is strongly activated in the EBVinfected cells induced to lytic cycle. Similar to other PKCs, activated PKCθ migrated at a lower molecular weight representing its catalytic domain, released from the intramolecular inhibitory domain, cleaved by caspase activation [67] . Moreover, upon T/B treatment, PKCθ localized to the nuclei, as other novel PKCs that translocate to the nuclei when activated [68] . PKCs have been reported to reduce Akt phosphorylation in keratinocytes [47] and, in agreement, in this study, we found that AKT was dephosphorylated by T/B, dependently on PKCθ activity. Several drugs can induce cancer cell death through AKT dephosphorylation [69] and this pathway is reported to be critical also for BL cell survival [47, 48] . While the involvement of the novel PKCs in apoptosis [70] [71] [72] has been extensively studied, their role in the autophagic process has been only recently begun to be explored [73] [74] [75] .
Here we show that besides promoting cell death, PKCθ induced autophagy and cell survival by activating p38 MAPK. Autophagy is indeed a cellular degradative process that helps cells to face stressful conditions, such as in the course of chemotherapy treatments [63] . It could also be the underlying mechanism of the p38-mediated pro-survival effect, previously observed by other authors, during the induction of the EBV lytic cycle [42] . Finally, autophagy, although subverted by EBV, was shown to play a positive role in viral lytic cycle [38, 39] . In this study we found that PKCθ and p38 promoted the EBV lytic cycle through autophagy induction. The PKCθ isoform has been already shown to be involved in autophagy induction, in the course of ER stress, in other cell types [40, 41] . Differently from EBV, in Kaposi's sarcoma human herpesvirus (KSHV) the lytic cycle was induced by PKCδ [76] and ERK activation [61] . However, autophagy was not investigated in these studies and, only later on, it has been reported that autophagy enhances KSHV replication [77] . A PKCδ-JNK axis has been shown to induce autophagy during hypoxic stressful conditions [78] as well as in the course of other cellular stresses [74, 79] . Moreover, the activation of PKC, induced by microtubule depolymerization, plays a role in the EBV reactivation from latency, through the downstream p38 and JNK phosphorylations, in nasopharyngeal carcinoma cells [34] . However, the involvement of the specific PKC isoforms was not investigated. In this study, we found that T/B activates PKCθ which, besides promoting the EBV lytic cycle, balances cell survival and cell death, by activating p38 and autophagy in one hand and by dephosphorylating AKT, on the other hand ( Fig. 8) .
A better understanding of the mechanisms regulating cell survival and the switch from latent to lytic cycle of EBV-infected cancer cells could help find new and more effective therapeutic approaches against EBVassociated malignancies. The finding that PKCθ is involved in EBV lytic cycle activation, encourages the searching for specific inhibitors of this molecule to control EBV reactivation. For example, sotrastaurin, an inhibitor of PKCs, including PKCθ, already experimented in organ transplantation [80] and very effective in inhibiting HIV reactivation [81] could have a broader effect in controlling the lytic cycle activation of different viruses, including EBV, in immuno-compromised patients.
